Octreotide

Endocrine / GI

Hormone secretion suppression

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide
Primary mechanism: Somatostatin receptor agonism
Primary market use: Acromegaly/NETs

Pharmacology

Molecular weight (Da): 1019.2
Oral bioavailability: N/A
Half-life: ~1.5-2 h
Route tags: Route-dependent / verify
Evidence level: Approved
Clinical status: Approved
Value-for-money score: 5 / 10

Reported protocol signal

No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Transient receptor pharmacology

Sources

https://www.fda.gov/drugs